E-CANE: a National Program of Remote Health Education Workshops (E-CANE)

January 5, 2026 updated by: Centre Hospitalier Universitaire de Nice

E-CANE: a National Program of Remote Health Education Workshops for Adolescents and Young Adults With Cancer

About 2000 adolescents and young adults (AYA) are diagnosed with cancer each year in France. This period of life is marked by a maturation and transition phase in various areas (psychological, physical, sexual, socio-professional...). Cancer occurrence has a very particular impact. AYAs diagnosed and treated for cancer have specific medical and psychosocial needs.In response to these specific needs, Therapeutic Education (TPE), initially developed for patients with chronic disease to help them acquire and maintain skills needed to better manage their daily lives with the constraints of their disease and its treatments, has now its place in cancerology. It has been shown to promote patient independence, improve therapeutic adherence (which is particularly poor in adolescents with cancer), and strengthen the therapeutic alliance between patients and their healthcare team. The strengthening of adolescents's self-care and adaptation skills is also recognized as essential during the experience of an oncological disease. In addition, over the past few years, in the context of the increasing use of the internet and digital technologies, particularly in the daily lives of young people, the implementation of remote TPE sessions (e-TPEs) has developed significantly. In cancerology, digital health interventions have the potential to expand access to the support available to youth with cancer. E-health offers flexibility to the delivery of psychosocial care and could help strengthen youth engagement and enable them to interact with professionals and other young people in a reassuring digital context.This project aims to demonstrate the feasibility of conducting remote health education workshops (e-TPE) for AYAs with cancer, regardless of their place of care in French territory. Following an educational assessment conducted by a professional trained in TPE, three digitalized workshops from the DYNAMO program, will be offered. The adherence to this type of educational interventions, the satisfaction of the patients and the professionals involved, but also the obstacles and difficulties encountered will be analyzed. Demonstrating the feasibility of these e-workshops would allow the spread and the enrichment of this type of interventions. This could facilitate their accessibility for all AYAs in French territory. At the end of this experiment, a randomized study could provide scientific evidence that the development of such a program is a relevant strategy to help young people with cancer manage the challenges associated with their diagnosis and treatment.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
48

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
    • Alpes Maritimes
      • Nice, Alpes Maritimes, France, 06000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adolescents and young adults between 15 and 25 years old with cancer followed in a French AYA center.

Description

Inclusion Criteria:

  • Patient with cancer diagnosed for at least one month.
  • Patient followed by an AYA Coordinating Nurse in one of the 27 French AYA centres.
  • Patient with Life expectancy ≥ 6 months.
  • Patient ealth status consistent with program requirements.
  • Karnosky index > 60%.
  • Patient who agrees to participate in the program and benefits from social security.
  • Patient able to understand, speak and read French.
  • Patient with no major cognitive impairment (assessed by the patient's referees).
  • Patient with no sensory disability.
  • Patient with access to a computer tool (smartphone, tablet, computer) and a WiFi or 4G network.
  • Non opposition from patient or their legal representative collected.
  • Patient who has signed the Privacy Policy.
  • Patient who consented to participate in PTE program.

Exclusion Criteria:

  • Patient unable to use informatic tools.
  • Known superior cognitive function disorders.
  • Progressive psychiatric pathology
  • Drug user or alcohol abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Remote Therapeutic Patient Education (e-TPE)
TPE is a set of practices aiming at allowing a patient to acquire and preserve abilities and skills to manage actively their disease, cares, and surveillance, in collaboration with the caregivers
Behavioral: Remote Therapeutic Patient Education (e-TPE)
TPE is a set of practices aiming at allowing a patient to acquire and preserve abilities and skills to manage actively their disease, cares, and surveillance, in collaboration with the caregivers

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Assess the patient's adherence to the implementation of remote health educational actions (e-TPE), in AYA patients with cancer undergoing treatment
Time Frame: Between 2 and 4 times over 18 months
Online self-administered satisfaction questionnaires filled out by the patients 70 questions, scores between 1 and 4, yes or no, multiple choice questions, open-ended questions.
Between 2 and 4 times over 18 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Assess the suitability of the pedagogical methods
Time Frame: 3 times over 12 months
Online self-administered satisfaction questionnaires filled out by the workshop hosts (12 questions) No scores, yes or no, open-ended questions.
3 times over 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier Universitaire de Nice

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 19, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 19, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 27, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 7, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 24OncoHémato01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings